Abata Therapeutics

This summer we’ve made significant strides advancing toward the clinic, with both an IND clearance and a Fast Track designation for ABA-101. Our rapid progress and our best-in-class approach to Treg development also enabled us to add expertise and a new investor: Bristol Myers Squibb. We look forward to sharing more news soon! https://lnkd.in/ehFPrJpi #drugdevelopment #biotechnology #MS

For the third year in a row, we partnered with Schools on Wheels of Massachusetts to fill backpacks with supplies for students impacted by homelessness. We continue to be inspired by this incredible initiative - supporting the academic, social, and emotional growth of local students. We’re happy to contribute in our small way to help kids feel a sense of belonging at school. #GivingBack #culture #CommunityEngagement https://www.sowma.org/

Thanks to #MultipleSclerosis News Today for a nice summary of our recent progress and the momentum behind our lead program, ABA-101, in development for the treatment of progressive multiple sclerosis. Clinical trial initiation for ABA-101 is imminent. We look forward to providing additional updates. #MS #drugdevelopment https://bit.ly/4dVPPqd

Check out what our CEO, Samantha Singer has to say about our recent FDA Fast Track designation for ABA-101 to treat progressive multiple sclerosis. This exciting milestone reminds us of our mission to bring meaningful new therapies to patients as quickly as we can. https://bit.ly/4dWJrOZ  #clinicaltrials #MS #biotech

The FDA Fast Track designation for ABA-101 for the treatment of progressive multiple sclerosis will enable us to expedite our efforts to bring ABA-101 to patients. This designation advances our mission, as initiation of a first-in-human (FIH) Phase 1 study is imminent. #clinicaltrials #drugdevelopment #MS https://bit.ly/4dWJrOZ

Bristol Myers Squibb’s equity investment in Abata supports our approach to Treg science. With proven leadership in cell therapy, immunology, and neuroscience, we are honored to have BMS as an investor.    CEO Samantha Singer on the significance of this investment and its potential to help advance our lead programs.    Learn more about last week’s announcement here: https://bit.ly/3SRZMMB

We are pleased to announce an equity investment from Bristol Myers Squibb to support the advancement of our Treg cell therapies into clinical development. This investment marks a significant milestone as we prepare to initiate trials for ABA-101 in progressive multiple sclerosis.     Read more:  https://bit.ly/3SRZMMB   #biotech #investment #drugdiscovery 

This week, our CEO Samantha Singer and COO John Trzupek will participate in a fireside chat on Tregs in inflammation and immunology with Nicole G. from Truist Securities. We're looking forward to a great discussion. #biotechnology #celltherapy #drugdiscovery

Abata co-founder and advisor Richard Ransohoff on the need in Progressive MS and ABA-101’s potential. ABA-101 may significantly benefit patients with Progressive MS who currently lack adequate treatment options. In preclinical studies, ABA-101 was shown to be safe and demonstrated tissue-specific trafficking, persistence, and robust suppression of inflammation, supporting its potential therapeutic effect. bit.ly/3LiotOa

Abata CEO Samantha Singer comments on the IND clearance of ABA-101, which validates our approach to leveraging Tregs to treat autoimmune diseases. Most importantly, it’s a potentially life-changing treatment for patients with Progressive MS. bit.ly/3LiotOa